Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics (NASDAQ: NEO) announced its participation in the BofA 2022 Healthcare Conference on May 12, 2022, in Las Vegas, with a fireside chat scheduled at 9:20 AM PT. Senior management will discuss the company's cancer-focused genetic testing services and operational strategies. The event will be webcasted live and accessible via the company’s website. NeoGenomics specializes in comprehensive oncology services and is dedicated to connecting patients with innovative therapies and clinical trials.
NeoGenomics (NASDAQ:NEO) reported its first-quarter results for 2022, showing a 1% increase in consolidated revenue to $117 million. The Clinical Services segment grew by 2% to $99 million, while Pharma Services revenue fell 4% to $18 million. Gross profit decreased by 8% to $38.2 million, resulting in a net loss of $49 million. Operating expenses surged 59% to $34 million, mainly due to acquisitions. Despite challenges, the company aims to improve performance and is actively searching for a new CEO.
NeoGenomics, Inc. (NASDAQ:NEO) has partnered with Eli Lilly to launch a sponsored testing program for patients with metastatic non-small cell lung cancer (NSCLC). This program offers the NeoTYPE® DNA and RNA Assay at no cost to eligible patients, helping them access targeted genomic testing. The initiative aims to enhance patient care by improving access to comprehensive tumor genomic profiling, which remains underutilized. Additionally, for patients unable to provide tissue samples, the InVisionFirst®-Lung Liquid Biopsy will be available at no cost.
NeoGenomics, Inc. (NASDAQ: NEO) announced significant findings from its subsidiary, Inivata, regarding the RaDaR assay for minimal residual disease (MRD) in stage III urothelial cancer, presented at the AACR Annual Meeting. Data from the NABUCCO study indicated that ctDNA detection post-treatment correlated with patient outcomes. Notably, 76% of patients with undetectable ctDNA post-treatment had a complete pathological response. These findings underscore RaDaR's potential for clinical application and future commercialization efforts by Inivata.
Biognosys has entered a strategic partnership with NeoGenomics (NASDAQ: NEO), enhancing NeoGenomics' multiomics solutions for biopharma clinical trials. This partnership will enable NeoGenomics labs to leverage Biognosys' advanced proteomics technology, including the TrueDiscovery™ platform. The collaboration aims to improve oncology drug development through joint scientific initiatives and presentations at the AACR Annual Meeting 2022. Initial efforts focus on combining proteomics and multiplexed immunofluorescence for analyzing tumor samples, potentially advancing biomarker identification for immunotherapy.
NeoGenomics has announced a strategic partnership with Biognosys AG to enhance its proteomics-based product capabilities in oncology drug development. This collaboration will improve diagnostics and clinical trials for their pharma clients. By integrating Biognosys' advanced proteomics platform with NeoGenomics' immuno-profiling tools, they aim to optimize research and identify key therapeutic markers in late-stage melanoma patients. The partnership will include joint presentations and initiatives to advance biopharma's oncology research.
NeoGenomics, Inc. (NASDAQ: NEO) plans to release its Q1 2022 financial results on April 27, 2022. A conference call to discuss these results is scheduled for 8:30 AM EDT on the same day, with access via phone and webcast. NeoGenomics specializes in cancer genetics testing and offers extensive services for pharmaceutical clients. The company adheres to data protection laws and invests in technologies to secure patient data.
NeoGenomics, Inc. (NASDAQ: NEO) announced the departure of CEO Mark Mallon, effective immediately, and appointed Lynn Tetrault as Executive Chair. The company expects first-quarter 2022 revenue below prior guidance of $118-$120 million and an EBITDA loss greater than anticipated, mainly due to increased Clinical Services costs. Guidance for 2022 has been withdrawn. Tetrault expressed commitment to improving performance and emphasized the leadership's continuity during the CEO search. Full Q1 results will be reported on April 27, 2022.
NeoGenomics (NASDAQ: NEO) announced new data supporting its RaDaR liquid biopsy test for early-stage non-small cell lung cancer (NSCLC), published in the Annals of Oncology. The LUCID study found that detectable ctDNA post-treatment was highly predictive of cancer recurrence, with specificity and positive predictive value at 100%. Notably, ctDNA detection preceded clinical recurrence by a median of 212.5 days. The study reinforces RaDaR's potential to improve patient outcomes by identifying those needing further treatment.
NeoGenomics, Inc. (NASDAQ: NEO) announced participation in key investor conferences. Senior management will engage in meetings and a fireside chat at the Raymond James 43rd Annual Institutional Investors Conference in Orlando on March 7, 2022, at 2:15 PM ET, and at Cowen's 42nd Annual Health Care Conference on March 9, 2022, at 1:30 PM ET. Both events will be webcast live on the company's website. NeoGenomics specializes in cancer genetics testing and offers extensive services to support oncology diagnosis and treatment.